Abstract 2505
Background
Worldwide, according to WHO 2014, over 19 million patients are in need of palliative care, 34% of them will die of cancer. Palliative care research brings many challenges. This metaresearch study aims to evaluate how clinical research on palliative care is conducted within the setting of incurable cancer.
Methods
Clinicaltrials.gov was searched to identify all registered studies investigating palliative care in patients with advanced or metastatic cancer. The EORTC QLQ-C15-PAL questionnaire was used to define the domains of interest. We excluded studies investigating cancer-directed therapy, management of cancer treatment-related adverse events, and diagnostic tests. Publication status was crosschecked using PubMed.
Results
Of 3950 identified studies, 514 studies were included. The most frequent reason for exclusion was cancer-directed therapy (2491). In 2007-2012, 161 studies were registered vs 245 in 2013-2018. Included studies were interventional (84%, 430/514) or observational (16%, 84/514). Most studies were sponsored by academia (79%), and conducted in North America (57%) or Europe (25%). 67% of studies evaluated a heterogeneous population (any tumour type). 60% were monocentric studies. Interventional studies most frequently investigated systemic drugs (34%, 148/430), behavioural interventions (29%, 125/430), and procedures for pain (24%, 103/430). Pain, quality of life and physical function were the most studied palliative issues (188, 95, 52 studies respectively). Fewer studies investigated health care planning (45), emotional function (35), appetite (22), social function (22), fatigue (20), dyspnea (18), sleep disturbance (5), cognitive function (5), nausea (4), and constipation (3). The most applied primary outcome measures were efficacy/symptom control (61.5%, 316), quality of life (14.2%, 73) and feasibility (11.7%, 60). Only 16% of the closed studies had published results.
Conclusions
The studies investigating palliative care in patients with incurable tumours constitute a very small part of cancer clinical research. More than one third of studies examine pain, leaving other palliative issues less explored in clinical research. Furthermore, the results of these studies are under reported in the literature.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3409 - Effect and safety of immune checkpoint inhibitors for brain metastases from non-small cell lung cancer
Presenter: Toshihiko Iuchi
Session: Poster Display session 1
Resources:
Abstract
3683 - Impact of Radiotherapy on efficacy of anti-programmed death 1 (PD-1) antibodies in metastatic NSCLC
Presenter: Evangeline Samuel
Session: Poster Display session 1
Resources:
Abstract
3924 - Pembrolizumab frontline monotherapy in patients with NSCLC and high PD-L1 expression: Real World Data from a European Cohort with focus on subgroups of interest
Presenter: Giannis Mountzios
Session: Poster Display session 1
Resources:
Abstract
3970 - Patients with metastatic non-small cell lung cancer and PD-L1 expression in Germany. Treatment and first outcome from the prospective German Registry Platform CRISP (AIO-TRK-0315)
Presenter: Martin Sebastian
Session: Poster Display session 1
Resources:
Abstract
5350 - The efficacy and safety of pembrolizumab as a first-line therapy in PD-L1 50% positive advanced NSCLC (HOPE-001)
Presenter: Motohiro Tamiya
Session: Poster Display session 1
Resources:
Abstract
3832 - Osimertinib in epidermal growth factor receptor (EGFR) T790M advanced non-small cell lung cancer (NSCLC): analysis of patients with central nervous system (CNS) metastases in a real-world study (ASTRIS)
Presenter: Giulio Metro
Session: Poster Display session 1
Resources:
Abstract
4082 - Real-world (RW) treatment patterns and outcomes for second-line (2L) therapy and beyond in patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC receiving a first-line (1L) first- or second-generation (1G/2G) EGFR tyrosine kinase inhibitor (TKI)
Presenter: Riyaz Shah
Session: Poster Display session 1
Resources:
Abstract
2855 - Impact of ramucirumab (RAM) + erlotinib (ERL) on EGFR mutations in circulating tumor DNA – The 1st report of a biomarker study in Japanese patients from RELAY: Global Ph3 study of ERL + RAM or placebo (PL) in 1L metastatic NSCLC with EGFR activating mutations
Presenter: Kazuto Nishio
Session: Poster Display session 1
Resources:
Abstract
2911 - Apatinib combined with EGFR - TKI in treating advanced non-small cell lung cancer with EGFR - TKI resistance
Presenter: Ruifen Tian
Session: Poster Display session 1
Resources:
Abstract
2100 - Updated analysis of a phase I trial of afatinib (Afa) and bevacizumab (Bev) in chemo-naïve patients (pts) with advanced non-small-cell lung cancer (NSCLC) harboring EGFR-mutations: OLCSG1404
Presenter: Takashi Ninomiya
Session: Poster Display session 1
Resources:
Abstract